EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1085-1089 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1085 - 1089
Section II - La réalité clinique
DOI https://doi.org/10.1051/medsci/200925121085
Published online 15 December 2009
  1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d’étude des lymphomes de l’adulte. J Clin Oncol 2005; 23 : 4117–26. [Google Scholar]
  2. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the german low-grade lymphoma study group. Blood 2005; 106 : 3725–32. [Google Scholar]
  3. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma : an East German study group hematology and oncology Study. J Clin Oncol 2007; 25 : 1986–92. [Google Scholar]
  4. Marcus RE, Solal-Celigny P, Imrie K, et al. MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (R-CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin’s lymphoma (NHL). Blood 2006; 108 : 481a. [Google Scholar]
  5. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients : results of the GELA-GOELAMS FL2000 study. Blood 2008; 112 : 4824–31. [Google Scholar]
  6. Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction : results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108 : 3295–301. [Google Scholar]
  7. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 2006; 108 : 4003–8. [Google Scholar]
  8. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19 : 2165–70. [Google Scholar]
  9. James DF, Castro JE, Sandoval-Sus JD, et al. Rituximab and high-dose methylprednisolone for the initial treatment of chronic lymphocytic leukemia is associated with promising clinical activity and minimal hematologic toxicity. Blood 2008; 112 : 47. [Google Scholar]
  10. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20 : 3262–9. [Google Scholar]
  11. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20 : 2453–63. [Google Scholar]
  12. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26 : 5156–64. [Google Scholar]
  13. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352 : 441–9. [Google Scholar]
  14. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma : five-year follow-up of Southwest oncology group protocol S9911. J Clin Oncol 2006; 24 : 4143–9. [Google Scholar]
  15. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine : results of a large international study. Blood 2002; 99 : 3554–61. [Google Scholar]
  16. Hillmen P, Skotnicki AB, Robak T, et al Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.J Clin Oncol 2007; 25 : 5616–23. [Google Scholar]
  17. Burnett AK, Kell WJ. The addition of gemtuzumab ozogamycin toinduction therapy for AML improves disease free survival without extra toxicity. Blood 2006; 108 : 13. [Google Scholar]
  18. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8 : results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15 : 3266–74. [Google Scholar]
  19. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84 : 2457–66. [Google Scholar]
  20. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside : ways to improve rituximab efficacy. Blood 2004; 104 : 2635–42. [Google Scholar]
  21. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002; 98 : 754–8. [Google Scholar]
  22. Salles G, Morschhauser F, Cartron G, et al. A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood 2008; 112 : 234. [Google Scholar]
  23. Bibeau F, Crapez E, Di Fiore F, et al. Association of FcgRIIa and FcgRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan. J Clin Oncol 2008; 26 : 11004. [Google Scholar]
  24. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of Trastuzumab-based therapy in patients With HER-2/neu–positive metastatic breast cancer. J Clin Oncol 2008; 26 : 1789–96. [Google Scholar]
  25. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8 : 34–47 [Google Scholar]
  26. Loisel S, Ohresser M, Pallardy M, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62 : 34–42. [Google Scholar]
  27. Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma : results of a phase II study. J Clin Oncol 2008; 26 : 2725–31. [Google Scholar]
  28. Lobry C, Weil R. New Bcl10 regulation mechanisms : a step in the comprehension of what has occurred in MALT lymphomas ? Med Sci (Paris) 2007; 23 : 353–5. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.